Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.375 CAD | -2.60% | 0.00% | -3.85% |
Mar. 27 | Transcript : Microbix Biosystems Inc. - Shareholder/Analyst Call | |
Mar. 14 | Microbix Says Clot-Buster Drug Project Advancing | MT |
Sales 2024 * | 18.59M 25.26M | Sales 2025 * | 21.32M 28.97M | Capitalization | 37.93M 51.53M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 2.04 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.78 x |
P/E ratio 2024 * |
18.8
x | P/E ratio 2025 * |
18.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.93% |
Latest transcript on Microbix Biosystems Inc.
1 day | -2.60% | ||
Current month | -5.06% | ||
1 month | -5.06% | ||
6 months | +17.19% | ||
Current year | -3.85% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Groome
CEO | Chief Executive Officer | - | 12-03-07 |
James Currie
DFI | Director of Finance/CFO | - | 16-10-31 |
Mark Luscher
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Cochran
BRD | Director/Board Member | - | 90-09-30 |
Peter Blecher
BRD | Director/Board Member | - | 05-12-05 |
Cameron Groome
CEO | Chief Executive Officer | - | 12-03-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 0.375 | -2.60% | 97,050 |
24-03-26 | 0.385 | +2.67% | 4,970 |
24-03-25 | 0.375 | +1.35% | 9,300 |
24-03-22 | 0.37 | -2.63% | 397,500 |
24-03-21 | 0.38 | +1.33% | 40,000 |
Delayed Quote Toronto S.E., March 27, 2024 at 03:51 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.85% | 37.93M | |
+9.16% | 45.97B | |
+54.42% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |